Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.38 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 6/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171341 | 0.86 | OPRL1 (0.33) | PGR | |
| SCHEMBL8266532 | 0.84 | PGR (0.35) | BACE1BACE2PGRNPY5RSLC6A2 | |
| SCHEMBL8267868 | 0.83 | OPRD1 (0.40) | SLC6A4 | |
| SCHEMBL12410382 | 0.83 | BACE1 (0.43) | BACE1PGR | |
| SCHEMBL8267865 | 0.83 | MAOA (0.37) | BACE1NPY5R | |
| SCHEMBL8266677 | 0.81 | BACE1 (0.45) | BACE1BACE2CTSDPGR | |
| SCHEMBL12410381 | 0.80 | BACE1 (0.46) | BACE1BACE2CTSDPGRNPY5R | |
| SCHEMBL8266536 | 0.80 | BACE1 (0.47) | BACE1BACE2CTSD | |
| SCHEMBL8267884 | 0.80 | BACE1 (0.42) | BACE1BACE2CTSDHSD11B1 | |
| SCHEMBL12410379 | 0.79 | PGR (0.44) | PGRNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BACE1 8/4885BACE2 30/4885CTSD 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.